Quick answer: Standard CRP and hs-CRP measure the same protein, C-reactive protein, but they use different assay sensitivities tuned for completely different clinical questions. Standard CRP (detection range roughly 10 to 1,000 mg/L) is the right test when a clinician suspects active infection, acute injury, or a flare of autoimmune disease. High-sensitivity CRP, or hs-CRP (detection range 0.1 to 10 mg/L), operates at a finer scale and is the test used to stratify cardiovascular risk in people who have no obvious inflammation at the moment. Ordering the wrong one does not add information; it wastes a draw and can give a falsely reassuring normal when real risk is present.
What is CRP and why does the test version matter?
C-reactive protein is a pentameric acute-phase protein made by the liver in response to interleukin-6 and other cytokines released during tissue damage or infection. In healthy adults it circulates at concentrations below 1 mg/L. During a serious bacterial infection or major trauma it can spike above 300 mg/L within 24 to 48 hours, making it one of the fastest and most dramatic acute-phase reactants in the body.
The clinical problem is that the same molecule spans three orders of magnitude depending on context. A standard CRP assay is calibrated and validated for the upper part of that range. Its lower detection limit is typically 5 to 10 mg/L, which means a reading of 0.8 mg/L and a reading of 4 mg/L both come back as “within normal” even though research shows those two values carry very different 10-year cardiovascular risk profiles. The hs-CRP assay is re-engineered, using nephelometry or immunoturbidimetry at higher antibody concentrations, to reliably distinguish values below 1 mg/L. That precision is the entire point of the higher-sensitivity version.
Understanding which assay you are looking at matters when you review your own lab printout. Quest Diagnostics reports both, but they appear under different CPT codes. Labcorp does the same. If a clinician orders a “CRP” without specifying hs, most hospital labs will default to the standard assay, which is designed for acute illness, not cardiovascular screening.
Standard CRP: the acute inflammation test
Standard CRP is the workhorse of hospital medicine. Clinicians use it to monitor sepsis severity, track whether antibiotics are working, assess a potential appendicitis, evaluate a lupus flare, and follow Crohn’s disease activity. The key property that makes it valuable here is the steep and rapid rise: CRP doubles approximately every 8 hours in early acute inflammation, peaks around 48 hours, and falls with a half-life of roughly 19 hours once the trigger resolves. That kinetics profile gives a near-real-time window into whether active tissue injury is occurring.
Standard CRP ranges
| Result (mg/L) | Typical interpretation |
|---|---|
| Below 10 | Normal; acute infection or major injury unlikely |
| 10 to 40 | Mild to moderate inflammation; viral illness, minor bacterial infection, inflammatory flare |
| 40 to 200 | Marked inflammation; active bacterial infection, serious flare, tissue injury |
| Above 200 | Severe bacterial infection, major trauma, severe burn; CRP alone is not diagnostic, always pair with clinical findings |
One thing clinicians know that patients often miss: CRP does not identify the source of inflammation. A CRP of 120 mg/L could be a community-acquired pneumonia, a perforated diverticulitis, or a severe rheumatoid flare. It is a signal for severity, not a diagnosis. That is why it is almost always ordered alongside a complete metabolic panel, CBC, and relevant imaging rather than in isolation. When you are building a complete blood panel, CRP sits in the inflammatory marker tier alongside ESR and ferritin.
hs-CRP: the cardiovascular risk stratification tool
hs-CRP earns its place in preventive cardiology because chronic low-grade vascular inflammation, the kind that drives atherosclerotic plaque progression, produces CRP elevations too small for the standard assay to detect. The Jupiter trial (2008), which enrolled nearly 18,000 adults with LDL below 130 mg/dL but hs-CRP at or above 2 mg/L, showed that rosuvastatin significantly reduced cardiovascular events in that population. That trial is the main reason US guidelines incorporated hs-CRP as a risk-enhancing factor.
The American Heart Association and the Centers for Disease Control co-published risk categories in 2003 that remain in clinical use today:
hs-CRP cardiovascular risk categories
| hs-CRP (mg/L) | Cardiovascular risk category |
|---|---|
| Below 1.0 | Low risk |
| 1.0 to 3.0 | Average risk |
| Above 3.0 | High risk |
| Above 10 | Likely acute inflammation; repeat in 2 to 3 weeks, do not use for cardiac risk scoring until resolved |
That last row matters. If an hs-CRP comes back above 10 mg/L, guidelines say to discard it for cardiac risk stratification purposes and repeat the test after the acute event resolves. This is the equivalent of not measuring fasting glucose during a hospitalization for trauma: the acute stress response makes the number uninterpretable for chronic risk purposes. The hs-CRP for heart risk should be measured in a metabolically stable, clinically well person.
hs-CRP is most useful as a tiebreaker. If your 10-year ASCVD risk sits in the intermediate range (7.5 to 20 percent) and your clinician is deciding whether to start a statin, an hs-CRP above 2 mg/L tips the balance toward treatment according to the 2019 ACC/AHA cholesterol guidelines. It is also one of the risk-enhancing factors in those same guidelines alongside lipoprotein(a), ABI, and coronary artery calcium score.
crp vs hs-crp: side-by-side comparison
| Feature | Standard CRP | hs-CRP |
|---|---|---|
| Detection range | ~5 to 1,000+ mg/L | ~0.1 to 10 mg/L |
| Clinical use | Acute infection, injury, autoimmune flare monitoring | Cardiovascular risk stratification, statin decision support |
| When to order | Symptomatic patient; suspected active inflammation | Asymptomatic well person; preventive cardiac workup |
| Normal threshold | Below 10 mg/L (most labs) | Below 1 mg/L (low CV risk) |
| Fasting required | No | No, but avoid during acute illness |
| CPT code (common) | 86140 | 86141 |
| Typical cash price | $15 to $60 at walk-in labs | $20 to $80 at walk-in labs |
| Covered by Medicare | Yes, with qualifying diagnosis | Yes, limited to cardiac risk indications |
When to use hs-CRP specifically
Order hs-CRP, not standard CRP, in these four situations. First, you are doing a preventive cardiovascular workup and want to understand whether chronic vascular inflammation is present. Second, your clinician is deciding whether intermediate ASCVD risk (7.5 to 20 percent) justifies statin therapy. Third, you have metabolic syndrome or insulin resistance and want a fuller picture of your inflammatory burden alongside fasting insulin and triglycerides. Fourth, you have had a prior cardiovascular event and want to track whether lifestyle interventions or statins are reducing systemic inflammation over time.
There is one important timing rule: do not check hs-CRP within three to four weeks of any significant illness, dental procedure, injury, or vaccination. Even a mild upper respiratory infection can push hs-CRP above 3 mg/L for several weeks after symptoms resolve, which would incorrectly flag you as high cardiovascular risk. This is a practical tip your lab report will not give you, but it is the reason guidelines say to repeat values above 10 mg/L rather than act on them immediately.
If you are reviewing the best biomarkers to test for a comprehensive health baseline, hs-CRP belongs in any panel aimed at cardiovascular or metabolic risk. Pairing it with apolipoprotein B, Lp(a), and fasting insulin gives a much more complete picture than cholesterol alone.
What a falsely elevated or falsely low hs-CRP looks like
Clinicians see two recurring patterns that confuse patients and sometimes confuse generalists who order the test less frequently.
False elevation scenarios: obesity alone can raise hs-CRP to 1 to 5 mg/L through adipose-tissue cytokine production, without any vascular inflammation. A person who is technically overweight may have a persistently elevated hs-CRP that reflects adiposity, not arterial disease. Gum disease (periodontitis) is another underappreciated driver: the chronic oral bacterial load produces a sustained low-grade acute-phase response, and studies have found hs-CRP values drop measurably after dental treatment. Hormone replacement therapy (oral estrogens in particular) raises hepatic CRP production and can falsely elevate hs-CRP by 50 to 100 percent compared to baseline.
False reassurance: immunosuppressive drugs (corticosteroids, biologics like TNF inhibitors, JAK inhibitors) blunt the CRP response even when active inflammation is present. A patient on prednisone for rheumatoid arthritis may have an hs-CRP of 0.4 mg/L while still having active synovitis measurable by MRI. In this context, relying on hs-CRP alone for disease monitoring is unreliable. The same caveat applies to statins: rosuvastatin lowers hs-CRP by roughly 37 percent independent of its LDL-lowering effect, so a patient on a high-intensity statin who shows hs-CRP of 0.7 mg/L might have had a baseline of 1.8 mg/L before treatment.
How much does each test cost?
Cash prices vary more than insurance-based prices. At Labcorp and Quest walk-in patient service centers as of 2026, standard CRP typically runs $15 to $50 and hs-CRP runs $25 to $80. CVS MinuteClinic and urgent care walk-ins that send out to reference labs often add a facility fee that pushes total cost to $60 to $120 for either test.
Both tests are HSA and FSA eligible as diagnostic lab tests. Medicare covers standard CRP under Part B with a diagnosis code for infection, inflammatory disease, or monitoring of a chronic inflammatory condition. For hs-CRP, Medicare coverage is narrower: it is covered when ordered as part of a cardiac risk assessment and the beneficiary has at least one ASCVD risk factor. Medicare Advantage plans follow similar rules but with variable cost-sharing.
Uninsured or underinsured patients get the best value through direct-access labs. Walk-in options like any Quest or Labcorp patient service center, or third-party ordering services, let you get an hs-CRP alone for around $25 to $40 without a physician visit. Many people who are already getting blood drawn anyway are better served by capturing a full inflammatory and metabolic baseline at once rather than a single marker. For a broader perspective on what that looks like, the superpower blood test review walks through a comprehensive panel approach.
If you are going to get one draw, make it count
Testing hs-CRP in isolation tells you one number without the context of your lipid particle counts, metabolic markers, or kidney function. If you are already getting blood drawn, it is often smarter to capture a full baseline at once. Here is how a full-body panel compares to ordering markers one at a time.
What people get wrong about interpreting their results
The most common mistake is treating a normal standard CRP as evidence of no cardiovascular risk. A standard CRP of 4 mg/L says nothing useful about your arteries because the assay cannot reliably distinguish 0.5 from 4 mg/L. Patients who get a standard CRP as part of a general wellness panel and see “normal” may have an hs-CRP of 3.5 mg/L, which puts them in the high cardiovascular risk category. If cardiovascular risk stratification is the goal, only the hs-CRP assay is fit for that purpose.
The second mistake is interpreting an isolated hs-CRP number without considering trend. A single value is a snapshot, not a story. hs-CRP varies day to day in a healthy person by roughly 30 to 40 percent due to circadian rhythm, sleep quality, and minor immune challenges. A more actionable approach is two measurements at least two weeks apart when the person is clinically well, averaged together, before making treatment decisions.
Third, many patients do not know that hs-CRP is also predictive of outcomes beyond heart disease. Elevated hs-CRP is independently associated with type 2 diabetes incidence, colorectal cancer, and depression, though the mechanism and directionality are still debated in each of those areas. This does not mean a high hs-CRP is a diagnosis of anything other than elevated systemic inflammation; it means inflammation is a systemic phenomenon and one biomarker often signals the need to look at the full picture. For example, pairing hs-CRP with cystatin c test results can reveal whether inflammation is also affecting early kidney function, since cystatin c is exquisitely sensitive to mild GFR decline that standard creatinine misses.
hs-CRP in the context of metabolic syndrome and insulin resistance
Visceral adiposity, hyperinsulinemia, and dyslipidemia all independently raise hs-CRP through overlapping cytokine pathways. In a person with metabolic syndrome who is not yet diabetic, hs-CRP is often elevated well before the Framingham Risk Score would flag them as high-risk. This is part of the argument for using hs-CRP as an early warning signal in middle-aged adults, particularly men in their 40s and women in the decade after menopause when cardiovascular risk accelerates.
Lifestyle interventions move the needle. Aerobic exercise at moderate to vigorous intensity for at least 150 minutes per week reduces hs-CRP by roughly 10 to 30 percent in intervention trials. Weight loss of 5 to 10 percent of body weight produces similar reductions. A Mediterranean-pattern diet consistently shows hs-CRP reductions of 0.3 to 0.5 mg/L compared to a Western diet in controlled studies. These are real, clinically meaningful changes: moving from 2.8 to 1.9 mg/L crosses the threshold from high to average cardiovascular risk.
If you want to see how hs-CRP fits alongside fasting insulin, triglycerides, and glucose when building a metabolic risk picture, the hs crp test page covers the assay itself in more depth, including how to prepare for the draw and how to read the full report. And if you are investigating whether insulin resistance is part of the picture, the c peptide test offers a complementary view of pancreatic output that glucose alone does not capture.
FAQ
Can I use a standard CRP result to calculate my cardiovascular risk?
No. Standard CRP does not have the resolution to score cardiovascular risk. The AHA/CDC risk categories and the ACC/AHA cholesterol guidelines specifically require hs-CRP, not standard CRP. If your lab report says “CRP” without the hs-CRP qualifier and your result is below 5 or 10 mg/L (marked normal), you do not have a useful cardiac risk number yet. Ask your clinician or order an hs-CRP specifically.
Do I need to fast before a CRP or hs-CRP test?
No fasting is required for either test. CRP and hs-CRP are not affected by food intake the way glucose and triglycerides are. That said, both tests are invalidated by acute illness, so avoid testing within three to four weeks of any significant infection, injury, surgery, or vaccination to get an interpretable cardiac risk result.
What is a good hs-CRP level?
Below 1.0 mg/L is considered low cardiovascular risk by AHA/CDC criteria. Many longevity-focused clinicians aim for below 0.5 mg/L as an optimal target, particularly in patients with other metabolic risk factors. Values consistently above 3.0 mg/L in a clinically well person warrant investigation into contributing causes: dental disease, obesity, sleep apnea, periodontal inflammation, or smoldering autoimmune activity.
Does a high hs-CRP mean I have heart disease?
Not directly. hs-CRP is a risk marker, not a diagnostic test. An elevated hs-CRP tells you that systemic inflammation is present and that your cardiovascular event risk may be higher than a simple LDL or cholesterol ratio would suggest. A coronary artery calcium (CAC) scan, a coronary CTA, or a stress test is required to determine whether actual atherosclerotic disease is present. Talk to a clinician about which follow-up test fits your risk profile.
Can statins lower hs-CRP?
Yes. High-intensity statins, particularly rosuvastatin and atorvastatin, lower hs-CRP by 30 to 40 percent independent of their LDL-lowering effect, a property sometimes called the pleiotropic anti-inflammatory effect of statins. The Jupiter trial used hs-CRP reduction as a secondary endpoint and found it tracked closely with cardiovascular event reduction. This is one reason clinicians sometimes monitor hs-CRP alongside LDL-C in statin-treated patients.
Is hs-CRP the same as ESR (erythrocyte sedimentation rate)?
No. ESR and CRP both measure inflammation but through completely different mechanisms. ESR measures how quickly red blood cells sediment in a tube, a process influenced by fibrinogen, immunoglobulins, and albumin. hs-CRP measures a specific protein directly. CRP rises and falls much faster than ESR (hours vs. days), making CRP better for monitoring acute disease activity. ESR is still used in certain contexts, particularly monitoring temporal arteritis and multiple myeloma, where it offers complementary information.
Can children get an hs-CRP test?
Technically yes, but cardiovascular risk stratification using hs-CRP is not part of standard pediatric preventive care in the US. Pediatric hs-CRP testing is occasionally ordered in children with familial hypercholesterolemia, obesity-related metabolic syndrome, or chronic inflammatory disease. Reference ranges for children differ from adult ranges, so adult cardiovascular risk categories should not be applied directly to pediatric results.
What is the difference between CRP and CRP-high sensitivity on my lab report?
They are two different assays run on the same protein. “CRP” on your report means standard CRP, calibrated for detecting elevated inflammation in the 10 to 1,000+ mg/L range. “CRP, High Sensitivity” or “hsCRP” means the assay is calibrated for the 0.1 to 10 mg/L range used in cardiovascular risk scoring. The number means nothing without knowing which assay produced it, because a “normal” result on a standard assay does not rule out an elevated hs-CRP.
